CN Patent

CN110869765A — 组合疗法

Assigned to ADC Therapeutics SA · Expires 2020-03-06 · 6y expired

What this patent protects

本发明涉及用于治疗病理病状例如癌症的组合疗法。特别地，本发明涉及包括用抗体药物缀合物(ADC)、第二药剂和任选地抗CD20药剂治疗的组合疗法。公开了抗体药物缀合物靶标CD19或CD22用于治疗癌症。公开了用于鉴别适合于治疗的个体的方法，其通过在患者正在或已经用抗CD20药剂诸如利妥昔单抗治疗时选择所述患者来进行。任选地，将ADC与另外的药剂例如化学治疗剂组合施用。

USPTO Abstract

本发明涉及用于治疗病理病状例如癌症的组合疗法。特别地，本发明涉及包括用抗体药物缀合物(ADC)、第二药剂和任选地抗CD20药剂治疗的组合疗法。公开了抗体药物缀合物靶标CD19或CD22用于治疗癌症。公开了用于鉴别适合于治疗的个体的方法，其通过在患者正在或已经用抗CD20药剂诸如利妥昔单抗治疗时选择所述患者来进行。任选地，将ADC与另外的药剂例如化学治疗剂组合施用。

Drugs covered by this patent

Patent Metadata

Patent number
CN110869765A
Jurisdiction
CN
Classification
—
Expires
2020-03-06
Drug substance claim
No
Drug product claim
No
Assignee
ADC Therapeutics SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.